Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The world's largest mattress supplier and manufacturer said its Mattress Firm, Dreams and Tempur Sealy businesses will operate as decentralized units under the Somnigroup umbrella after the name ...

Shares of Google parent Alphabet slump after quarterly revenue misses analysts’ expectations, AMD’s data-center revenue ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google parent's cloud revenue falls short of estimates, and Advanced Micro Devices ...

$75 billion capital expenditure in 2025: A 12% total revenue rise was a miss. But CEO Sundar Pichai still puts Alphabet at ...

European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...